Enanta Pharmaceuticals (ENTA) Current Leases (2016 - 2026)

Enanta Pharmaceuticals has reported Current Leases for 10 years, with the latest figure at $3.8 million in Q1 2026.

• For the quarter ending Q1 2026, Current Leases rose 71.17% year-over-year to $3.8 million; the trailing twelve-month figure through Mar 2026 stood at $3.8 million (up 71.17% YoY), and the FY2025 full-year result was $3.1 million, up 106.43% from the prior year.
• Current Leases for Q1 2026 stood at $3.8 million, up from $3.3 million in the prior quarter.
• The five-year high for Current Leases was $5.4 million in Q2 2023, with the low at $1.0 million in Q4 2024.
• Historically, Current Leases has averaged $3.3 million across 5 years, with a median of $3.1 million in 2025.
• Annual changes were most pronounced in 2024 — Current Leases slumped 79.74% — and 2025, when it jumped 226.74%.
• Enanta Pharmaceuticals' Current Leases stood at $3.5 million in 2022, then surged by 42.46% to $5.0 million in 2023, then tumbled by 79.74% to $1.0 million in 2024, then jumped by 226.74% to $3.3 million in 2025, then increased by 14.36% to $3.8 million in 2026.
• The last three Current Leases figures came in at $3.8 million (Q1 2026), $3.3 million (Q4 2025), and $3.1 million (Q3 2025), per Business Quant data.